small RNA binding exonuclease protection factor La like 3, pseudogeneGenealiases: []
Q-omics provides the consensus-scored SSBL3P profile across patient tissues and cancer cell-line models. SSBL3P expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SSBL3P is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, SSBL3P RNA expression shows 6,527 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, BRCA, and STAD as cancer lineages where SSBL3P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SSBL3P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SSBL3P survival associations across molecular data types. SSBL3P RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SSBL3P RNA expression–survival associations across cancer types. High SSBL3P expression shows unfavorable associations in KIRC, ACC, SKCM, OV and COAD, but favorable associations in LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SSBL3P RNA expression.
This table summarizes SSBL3P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SSBL3P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SSBL3P shows lower tumor expression in BRCA and higher tumor expression in KIRC and COAD. The BRCA box plot shows higher SSBL3P RNA expression in normal versus tumor tissue (log2 FC = −0.041, t-test p < 0.001).
This table shows molecular features associated with SSBL3P in patient tissues and cancer cell lines. In patient samples, SSBL3P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
